NCT05870709View on ClinicalTrials.gov

Real World, Pharmacy-assessed Adherence to New Onset Entresto® (Sacubitril/Valsartan) in Patients With Chronic Heart Failure

WithdrawnOBSERVATIONAL

Timeline

Start Date

May 15, 2023

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2024

Conditions

Heart Failure

Interventions

OTHER

sacubitril/valsartan

There is no treatment allocation. Patients with a first ambulatory sacubitril/valsartan prescription who are interested in study participation will be enrolled.